Hologic forecasts lower-than-expected annual sales on equipment shipping halt
Nov 4 (Reuters) -Medical technology company Hologic HOLX.O said on Monday it anticipates annual revenue below average analysts'estimates, hurt by ongoing temporary pause on shipping of its bone density scanning machines.
The Marlborough, Massachusetts-based company manufactures and supplies viral load tests, molecular diagnostics assays, medical imaging systems and surgical products focused on women's health.
Shares of the company fell 2.05% to $82 in extended trading.
The company expects 2025 revenue in range of $4.15 billion to$4.20 billion, below average analysts'estimate of $4.21 billion.
The company said its full-year forecast included an expected impact from ongoing temporary halt in shipping of its bone density scanning machine, Horizon DXA systems.
Sales for theskeletal health business — which includes X-ray systems and other products that help with minimally invasive surgical procedures — totalled $12.7 million, below analysts' estimates of $15.1 million, according to data compiled by LSEG.
However, the company expects to resume shipping of Horizon DXA systems in the latter half of first quarter.
The recent IV fluid shortage from hurricanes will hurt the company's elective breast and surgical procedures, impacting its diagnostics products sale, Hologic's CFO Karleen Oberton said in the earnings call.
Hologic also forecast annual adjusted profit per share in range of $4.25-$4.35, with its mid-point in line with analysts' expectations.
On an adjusted basis, Hologic posted a profit of $1.01 per share, in line with analysts' estimates. Hologic also beat sales expectations for the fourth quarter.
Reporting by Sruthi Narasimha Chari in Bengaluru; editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
